Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Richard Whitley
University of Alabama at Birmingham, Department: Internal Medicine/medicine
Should you be removed from our database? Contact us at [email protected]. Read more below.
Catherex, Inc.
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
The investigator’s IP is related to that which is used in the project and thus its value could be impacted by the results.
The outcome of the research is of significant business interest to the entity and therefore the financial interest could likely change based on the research results.
Inhibition of Herpes Simplex Virus Type 2 by Tenofovir
Public Health Relevance: Infection with Herpes Simplex Virus Type 2 in immunocompromised populations, such as patients with HIV, is of particular concern because it can cause severe disease and harbor resistance to drug treatment in this population. There is need to identify new agents that effectively prevent and treat HSV-2, especially in HIV infected populations. In this grant, I will investigate Tenofovir's (TDF) anti-HSV-2 activity in vivo and in vitro.
Filed on May 14, 2013.
Tell us what you know about Richard Whitley's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Richard Whitley”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Richard Whitley | University of Alabama at Birmingham | Conflict of Interest | Catherex, Inc. | $0 - $4,999 |
| Richard Whitley | University of Alabama at Birmingham | Conflict of Interest | Gilead Sciences | >$600,000 |
| Richard Whitley | University of Alabama at Birmingham | Conflict of Interest | Catherex, Inc. | $0 - $4,999 |
| Richard Whitley | University of Alabama at Birmingham | Conflict of Interest | Catherex, Inc. | $0 - $4,999 |
| Richard Whitley | University of Alabama at Birmingham | Conflict of Interest | AETTIS, INC. | $0 - $4,999 |
| Richard Whitley | University of Alabama at Birmingham | Conflict of Interest | GIlead Sciences | Value cannot be readily determined |
| Richard Whitley | University of Alabama at Birmingham | Conflict of Interest | Gilead Sciences | Value cannot be readily determined |
| Richard Whitley | University of Alabama at Birmingham | Conflict of Interest | Gilead Sciences | Value cannot be readily determined |
| Richard Whitley | University of Alabama at Birmingham | Conflict of Interest | CATHEREX | $0 - $4,999 |
| Richard Whitley | University of Alabama at Birmingham | Conflict of Interest | GIlead Sciences | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.